StemInov
StemInov is developing an allogenic cell therapy treatment in the field of inflammatory pathologies
Status
IP Type
PCT
Time
19 years
Countries
Coverage
MESENCHYMAL STEM CELLS OBTAINED FROM WHARTON’S JELLY FOR THE TREATMENT OF SEPSIS
Know more of this patent
This information is confidential, do not share or copy.
You can visit their website or
Under evaluation at least till: 14th of July 2023
KEEP REVIEWING